Executive Vice President, Chief Medical Officer and Chief Science Officer
Pierre-Yves was appointed Chief Medical Officer in January 2023 with responsibility for Medical Affairs, Pharmacovigilance, Quality Assurance, Value & Access and Bioethics. He becomes Chief Science Officer in March 2024 with responsibility for overseeing Ferring’s research and development.
Pierre-Yves previously held the position of Senior Vice President, Head of Global Medical Affairs for Neurology and Immunology at Merck KGaA/EMD Serono, based in Boston, USA. Prior to this, he spent over 14 years at Eli Lilly, holding leadership roles in Medical Affairs, Global Clinical Development, Clinical Pharmacology and Discovery Research.Pierre-Yves also spent seven years as Chief Medical Officer for Eli Lilly Japan, where he was involved in the launch of numerous new molecular entities.
He holds a medical degree from the University of Lausanne, and received specialty training in Paediatrics at the Universities of Lausanne and Geneva. He obtained his sub-specialty in Pulmonary Medicine and his PhD in Molecular Biology from the Cincinnati College of Medicine.
